Where can I learn more about this study?
You can find more information about this study on the websites listed below. If
more information about the study results is available, it can also be found here.
> www.clinicaltrials.gov. Once you are on the website, type “NCT03106428”
into the search box and click “Search”.
> www.AstraZenecaClinicalTrials.com. Once you are on the website, type
“D8540C00001” into the search box, and click “Find a Study”.
Full Study Title: A Phase I Multicenter, Open-label, Dose-escalation and
Dose expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in
Patients with Selected Relapsed/Refractory Hematological Malignancies
AstraZeneca Protocol Number: D8540C00001
National Clinical Trials Number: NCT03106428
MedImmune, LLC, a member of the AstraZeneca Group, sponsored this study
and has its headquarters at 1 MedImmune Way, Gaithersburg, MD 20878, USA.
The phone number for the AstraZeneca Information Center is +1-877-240-9479.
Thank you
Clinical study participants and their families belong to a large community of
people who take part in clinical research around the world. They help researchers
answer important health questions and find medical treatments for patients.
The Center for Information & Study on Clinical Research Participation (CISCRP) is a non-profit organization focused on
educating and informing the public about clinical research participation. CISCRP is not involved in recruiting participants
for clinical studies, nor is it involved in conducting clinical studies.
CISCRP | One Liberty Square, Suite 1100 • Boston, MA 02109 | 1-877-MED-HERO | www.ciscrp.org
Version 1.0 2021_04_20
14 | Clinical Study Results